Critical comment: analyzing the effect of novel therapies on cytokine expression in inflammatory bowel disease: do cytokine levels reflect clinical response?

2006 ◽  
Vol 21 (6) ◽  
pp. 505-507 ◽  
Author(s):  
B. M. Wittig ◽  
M. Zeitz
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Response ◽  
Bowel Disease ◽  
Cytokine Expression ◽  
Critical Comment ◽  
Novel Therapies ◽  
Cytokine Levels ◽  
Inflammatory Bowel

Mucosal cytokine expression, cellular markers and adhesion molecules in inflammatory bowel disease

1999 ◽  
Vol 11 (3) ◽  
pp. 267-276 ◽  
Author(s):  
Alexander Woywodt ◽  
Diether Ludwig ◽  
Petra Neustock ◽  
Andrea Kruse ◽  
Karsten Schwarting ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Adhesion Molecules ◽  
Bowel Disease ◽  
Cytokine Expression ◽  
Inflammatory Bowel ◽  
Cellular Markers

scholarly journals An Overview of Novel and Emerging Therapies for Inflammatory Bowel Disease

2020 ◽  
pp. 91-101
Author(s):  
Sumona Bhattacharya Sumona Bhattacharya ◽  
Raymond K. Cross Raymond K. Cross
Keyword(s):  
Ulcerative Colitis ◽  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Severe Disease ◽  
Gastrointestinal Symptoms ◽  
The Novel ◽  
Novel Therapies ◽  
Emerging Therapies ◽  
Sphingosine 1 Phosphate ◽  
Inflammatory Bowel

Inflammatory bowel disease, consisting of Crohn’s disease and ulcerative colitis, causes chronic gastrointestinal symptoms and can lead to morbidity and mortality if uncontrolled or untreated. However, for patients with moderate-to-severe disease, currently available therapies do not induce or maintain remission in >50% of patients. This underscores the need for additional therapies. In this review, the authors detail the novel therapies vedolizumab, tofacitinib, and ustekinumab and delve into therapies which may come onto the market within the next 10 years, including JAK-1 inhibitors (filgotinib and upadacitinib), IL-23 inhibitors (guselkumab, mirikizumab, and risankizumab), the anti-β4β7 and anti-βEβ7 integrin monoclonal antibody etrolizumab, the sphingosine-1-phosphate subtypes 1 and 5 modulator ozanimod, and mesenchymal stem cells. Further studies are required before these emerging therapies gain approval.

scholarly journals W1265 Fecal Calprotectin Values in Inflammatory Bowel Disease Patients After Induction Course of Anti-TNF Agents: Correlation With the Clinical Response

2010 ◽  
Vol 138 (5) ◽  
pp. S-686
Author(s):  
Luisa Guidi ◽  
Manuela Marzo ◽  
Carla Felice ◽  
Gianluca Andrisani ◽  
Lucia Sparano ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Response ◽  
Bowel Disease ◽  
Fecal Calprotectin ◽  
Inflammatory Bowel

scholarly journals Cannabidiol and palmitoylethanolamide are anti-inflammatory in the acutely inflamed human colon

2017 ◽  
Vol 131 (21) ◽  
pp. 2611-2626 ◽  
Author(s):  
Daniel G. Couch ◽  
Chris Tasker ◽  
Elena Theophilidou ◽  
Jonathan N. Lund ◽  
Saoirse E. O’Sullivan
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Human Colon ◽  
Interferon Γ ◽  
Cytokine Levels ◽  
Drug Treatments ◽  
Inflammatory Bowel ◽  
Anti Inflammatory ◽  
Trpv1 Antagonist ◽  
Factor Α

Objective: We sought to quantify the anti-inflammatory effects of two cannabinoid drugs, cannabidiol (CBD) and palmitoylethanolamide (PEA), in cultured cell lines and compared this effect with experimentally inflamed explant human colonic tissue. These effects were explored in acutely and chronically inflamed colon, using inflammatory bowel disease and appendicitis explants. Design: Caco-2 cells and human colonic explants collected from elective bowel cancer, inflammatory bowel disease (IBD) or acute appendicitis resections, and were treated with the following drug treatments: vehicle, an inflammatory protocol of interferon γ (IFNγ) and tumour necrosis factor α (TNFα; 10 ng/ml), inflammation and PEA (10 µM), inflammation and CBD (10 µM), and PEA or CBD alone, CBD or vehicle were added simultaneously with IFNγ. Nine intracellular signalling phosphoproteins were determined by multiplex. Inflammatory cytokine secretion was determined using ELISA. Receptor mechanisms were investigated using antagonists for CB1, CB2, PPARα, PPARγ, TRPV1 and GPR55. Results: IFNγ and TNFα treatment increased phosphoprotein and cytokine levels in Caco-2 cultures and colonic explants. Phosphoprotein levels were significantly reduced by PEA or CBD in Caco-2 cultures and colonic explants. CBD and PEA prevented increases in cytokine production in explant colon, but not in Caco-2 cells. CBD effects were blocked by the CB2 antagonist AM630 and TRPV1 antagonist SB366791. PEA effects were blocked by the PPARα antagonist GW6471. PEA and CBD were anti-inflammatory in IBD and appendicitis explants. Conclusion: PEA and CBD are anti-inflammatory in the human colon. This effect is not seen in cultured epithelial cells. Appropriately sized clinical trials should assess their efficacy.

Tu1885 Pregnane X Receptor Stimulation Reduces NF-κB Mediated Cytokine Expression in Intestinal Biopsies From Inflammatory Bowel Disease Patients

2012 ◽  
Vol 142 (5) ◽  
pp. S-869
Author(s):  
J. Jasper Deuring ◽  
Timon Q. van den Berg ◽  
Ernst J. Kuipers ◽  
Maikel P. Peppelenbosch ◽  
Colin de Haar ◽  
...  
Keyword(s):  
Inflammatory Bowel Disease ◽  
Bowel Disease ◽  
Pregnane X Receptor ◽  
Cytokine Expression ◽  
Receptor Stimulation ◽  
Inflammatory Bowel

scholarly journals Outcome of Cytomegalovirus Colitis in Inflammatory Bowel Disease with Different Regimes of Ganciclovir

2018 ◽  
Vol 10 (4) ◽  
pp. 220-229 ◽  
Author(s):  
Iftikhar Ahmed ◽  
Wael Kassem ◽  
Yazen Salam ◽  
Manuele Furnari ◽  
Tina Mehta
Keyword(s):  
Inflammatory Bowel Disease ◽  
Clinical Outcome ◽  
Clinical Response ◽  
Bowel Disease ◽  
Oral Treatment ◽  
Indeterminate Colitis ◽  
Cmv Infection ◽  
Poor Outcome ◽  
Inflammatory Bowel ◽  
Cmv Colitis

BACKGROUND Cytomegalovirus (CMV) infection is common in individuals with inflammatory bowel disease (IBD) and is responsible for relapse, increased severity, and poor outcome if left untreated. Ganciclovir is the mainstay of treatment but data regarding its use, mode of administration, and duration of treatment is poorly described. We reviewed the practice of treating CMV colitis with different regimes of ganciclovir at a district NHS hospital to compare the clinical outcome. METHODS 35 patients with IBD and concurrent diagnosis of CMV infection were evaluated. The parameters studied were clinical outcome in term of clinical response, length of hospital stay, readmission, or colectomy with three different regimes of ganciclovir, in addition to treatment for IBD. RESULTS 35 patients with IBD (ulcerative colitis = 23, Crohn’s disease = 5, Indeterminate colitis = 7) and positive diagnosis of CMV infection were studied. Clinical outcome with two weeks of intravenous (IV) ganciclovir regime was superior than one week of IV ganciclovir and two weeks of oral Valganciclovir in term of clinical response on day 15 (95.8% vs 74%, 24.3%, respectively p = 0.45) and colectomy rate within 3 months (6.25% vs 27.3%, vs 25%, respectively). CONCLUSION CMV colitis is associated with poor outcome in patient with IBD if left untreated. 2 weeks IV ganciclovir was associated with a better outcome than 1 week of IV treatment or oral treatment.

Sign in / Sign up

Export Citation Format

Share Document